In Vivo Epigenetic Reprogramming: A New Approach to Combating Glaucoma

BY YUANCHENG RYAN LU, PHD; DAVID A. SINCLAIR, PHD; MEREDITH S. GREGORY-KSANDER, PHD; AND BRUCE R. KSANDER, PHD

Glaucoma is a leading cause of age-related blindness worldwide, characterized by a progressive loss of retinal ganglion cells (RGCs) and their axons. Could reversing the age of RGCs restore youthful function that would rescue vision lost because of glaucoma? A recent study sought to answer this question.1

Although glaucoma is a multifactorial disease for which genetic studies have identified numerous risk factors, by far the most significant risk factor associated with glaucoma is aging. Surprisingly, experimental evidence suggesting the possibility of reversing the age of cells has been around for some time. DNA methylation pattern changes predictably during aging and can therefore be used to reliably estimate biological age (known as DNA methylation age).2,3 Both somatic cell nuclear transplantation4 and the induction of pluripotent stem cells5 from aged mammalian cells could reset the DNA methylation age of the original genome2,6 and produce new individuals with normal lifespans.2 However, in both cases, reprogramming is accompanied by dedifferentiation and loss of cellular identity. To reverse the age of cells within the tissues of a living organism and keep the cellular identity intact, a new approach is required.

A NOVEL APPROACH TO EPIGENETIC REPROGRAMMING

In this new study,1 we employed a novel form of epigenetic reprogramming to reverse the aging of RGCs. Unlike a previous in vivo epigenetic reprogramming study,7 our approach used only three of the four famous Yamanaka reprogramming factors, Oct4, Sox2, and Klf4 (OSK). The oncogene c-Myc was excluded to avoid tumorigenesis. In addition, the reprogramming genes were delivered to RGCs through adeno-associated virus (AAV), a clinically approved gene therapy cargo,9 and engineered under tight control of the doxycycline-inducible promoter. The length of time epigenetic reprogramming lasts can be determined by administering doxycycline to mice via drinking water. Even when OSK genes were consistently expressed in RGCs for 15 months, there was no evidence of cellular dedifferentiation or retinal structure alterations.

Mice experience age-related vision loss similarly to humans. By the time mice are 12 months old, they have experienced a significant loss of visual function, as detected by pattern electroretinogram (pERG) and optomotor reflex (OMR). When in vivo epigenetic reprogramming using OSK was induced in the RGCs of these aging mice, it significantly increased their vision, as detected by pERG and OMR. This change in function coincided with a reversal of the DNA methylation age and restoration of a youthful transcriptome and methylome in RGCs, directly linking the reversal of cellular age with the restoration of RGC function and vision.

The power of this technology to counteract RGC injury was first tested in an optic nerve crush model,1 an acute model of optic nerve injury,10 where a mechanical crush was introduced at the optic nerve head, causing the death of 80% of the RGCs and axons within 2 weeks. OSK-triggered epigenetic reprogramming induced robust axon regeneration, a capacity that is lost in mice within days after birth. Surprisingly, even when reprogramming was induced after the crush injury had already occurred, axons were still regenerated, an effect that has not yet been achieved by other interventions.
Encouraged by the effect of epigenetic reprogramming in the optic nerve crush injury, we next tested OSK reprogramming using the microbead model of glaucoma in mice. The injection of microbeads into the anterior chamber blocks the aqueous humor outflow pathway, leading to elevated IOP and a loss of RGCs and axons by 4 weeks, which results in a significant reduction in pERG and OMR, an effect not observed in the control groups (Figure).

**THERAPEUTIC POTENTIAL FOR GLAUCOMA**

Rescue of visual function by a treatment that is initiated after glaucomatous damage has occurred has significant clinical potential. Our hypothesis is that epigenetic reprogramming rejuvenates RGCs that are dysfunctional but not dead by restoring a youthful transcriptome and methylome that allows the injured cells to recover from the injury, something that aged RGCs are incapable of doing.

There have been numerous approaches to treating glaucoma in rodent models. These include targeting inflammation, apoptosis, prosurvival, and metabolic pathways. The majority of these studies initiated treatment before or during the initial stages of glaucoma when IOP was increasing but...
"EPIGENETIC REPROGRAMMING REJUVENATES RGCS THAT ARE DYSFUNCTIONAL BUT NOT DEAD BY RESTORING A YOUTHFUL TRANSCRIPTOME AND METHYLMONE THAT ALLOWS THE INJURED CELLS TO RECOVER ... SOMETHING THAT AGED RGCS ARE INCAPABLE OF DOING."

no axonal damage or decrease in visual function had yet occurred. Although these experiments demonstrated neuroprotection that prevented neuronal damage, their mode of action may limit their window of efficacy to patients in earlier stages of the disease.

CONCLUSION

Epigenetic reprogramming is a new form of gene therapy that can reverse the age of cells in mice, restoring youth to their transcriptome and methylome. Importantly, this rejuvenating effect can allow the retina to recover functions that were lost with aging, such as axon regeneration and sensory perception. OSK-mediated epigenetic reprogramming appears to hold great therapeutic potential in humans, not only for glaucoma but also for a variety of age-related eye diseases (eg, age-related macular degeneration) and for other tissues affected by age-induced cellular dysfunction.8

Related lab work was supported by the Harvard Medical School Epigenetics Seed Grant and Development Grant, The Paul F. Glenn Foundation for Medical Research, and a gift from E. Schulak.